

Response to

Fisher, Benjamin A; Emery, Paul; Pitzalis, Costantino; Bombardieri, Michele; Bowman, Simon J

DOI:

[10.1136/annrheumdis-2018-213340](https://doi.org/10.1136/annrheumdis-2018-213340)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Fisher, BA, Emery, P, Pitzalis, C, Bombardieri, M & Bowman, SJ 2018, 'Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?', *Annals of the Rheumatic Diseases*. <https://doi.org/10.1136/annrheumdis-2018-213340>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

"This article has been accepted for publication in *Annals of the Rheumatic Diseases* 2018 following peer review, and the Version of Record can be accessed online at <http://dx.doi.org/10.1136/annrheumdis-2018-213340>

© 2018. Reuse of this manuscript version is permitted strictly pursuant to the terms of the CC-BY-NC-ND 4.0 license: <http://creativecommons.org/licenses/by-nc-nd/4.0/>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Response to: Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?

Benjamin A. Fisher^{1,2,3}, Paul Emery^{4,5}, Costantino Pitzalis⁶, Michele Bombardieri⁶, and Simon J Bowman^{1,2,3}, on behalf of co-authors.

1. National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre
2. Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
3. Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA,
5. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
6. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, London, UK.

We thank Mossel and colleagues for their interest in our work.[1, 2] They raise a number of limitations that we acknowledge and have discussed. In addition we agree that an understanding of the pathology underlying the abnormal salivary gland ultrasound findings in Sjögren's syndrome is an important objective to help establish the validity of this tool as a potential outcome measure in clinical trials. As both we and Mossel and colleagues discuss, we did not observe a difference in hypoechoic areas between rituximab and placebo. Similar hypoechoic areas can be observed in longstanding post-radiotherapy salivary glands where inflammatory cell infiltrate is variable and of a differing pattern.[3-5] Furthermore the pattern of hypoechoic areas on ultrasound in Sjögren's syndrome is reminiscent of sialography findings which are characterised by contrast defined changes that include destructive and cavitatory stages.[6] Consequently late-stage hypoechoic lesions may reflect potentially irreversible damage rather than ongoing inflammatory lesions. However this would not explain the reported improvement in such hypoechoic lesions following rituximab in a single centre substudy of the French TEARS trial.[7] Our total ultrasound score (TUS) was designed some time ago,[1] and prior to more recent consensus work,[8] and we would not necessarily advocate this score above others for future studies. A greater number of categories for the number and sizing of hypoechoic lesions might offer greater sensitivity to change, be that an improvement or slowing of progression. However, creation of a larger yet reliable dynamic range for the measurement of hypoechoic lesions with such an operator dependent technique, in a multicentre study, may require some form of digital image analysis. Secondly, we also agree that salivary gland histopathology may offer a useful window on drug efficacy or lack thereof in clinical trials in Sjögren's syndrome. We also advocate the need for standardisation and have argued that the focus

score alone may be insufficient as an outcome measure,[9, 10] although this has yet be proved in the context of a drug that also clearly improves clinical manifestations in a double blind multicentre study. Histology may also provide a means of predicting patients that might respond to B cell depleting therapies; such analyses are underway in the TRACTISS biopsy substudy and it will be interesting to see if we can replicate the reported associations between B cell infiltration and response, whether positive or negative.[11-13] However, preliminary data from the ongoing histopathology analysis of TRACTISS also confirmed that no improvement in the focus score could be observed between the active and the placebo arm of the study. It will be of interest to correlate these findings with the baseline and post-treatment number and size of the hypoechoic areas observed at ultrasound. Although Mossel et al advocate the use of parotid histopathology for such repeated measures,[2], data from their own group suggest that the diagnostic value of parotid and minor salivary gland histopathology is very similar,[14] with the exception that lymphoepithelial lesions that are more common in parotid glands compared with minor salivary glands. We would argue that minor salivary glands are far more commonly used as a routine diagnostic tool and are therefore more amenable for use in multicentre studies. Whether the reproducibility of histological measures, such as focus score, mean focus area and area of infiltration, differ between repeat biopsies of the parotid versus minor salivary glands is unknown but would help inform this debate. In conclusion, we agree with Mossel et al that further validation work on ultrasound as a potential outcome measure, and standardisation of histopathology, is both warranted and highly desirable.

1. Fisher BA, Everett CC, Rout J, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Carr A, Pease CT, Price EJ *et al*: **Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.** *Ann Rheum Dis* 2018, **77**(3):412-416.
2. Mossel E, Delli K, Arends S, Haacke EA, van der Vegt B, van Nimwegen JF, Stel AJ, Spijkervet FKL, Vissink A, Kroese FGM *et al*: **Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjogren's syndrome?** *Ann Rheum Dis* 2018.
3. Cheng SC, Wu VW, Kwong DL, Ying MT: **Assessment of post-radiotherapy salivary glands.** *The British journal of radiology* 2011, **84**(1001):393-402.
4. Radfar L, Sirois DA: **Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: an animal model for human radiation-induced salivary gland injury.** *Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics* 2003, **96**(3):267-274.
5. Teshima K, Murakami R, Yoshida R, Nakayama H, Hiraki A, Hirai T, Nakaguchi Y, Tsujita N, Tomitaka E, Furusawa M *et al*: **Histopathological changes in parotid and submandibular glands of patients treated with preoperative chemoradiation therapy for oral cancer.** *Journal of radiation research* 2012, **53**(3):492-496.

6. Rubin P, Holt JF: **Secretory sialography in diseases of the major salivary glands.** *The American journal of roentgenology, radium therapy, and nuclear medicine* 1957, **77**(4):575-598.
7. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, Marhadour T, Bressollette L, Gestin S, Pers JO, Nowak E, Saraux A: **Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjogren's Syndrome.** *Arthritis Rheumatol* 2015, **67**(6):1623-1628.
8. Jousse-Joulin S, Nowak E, Cornec D, Brown J, Carr A, Carotti M, Fisher B, Fradin J, Hocevar A, Jonsson MV *et al*: **Salivary gland ultrasound abnormalities in primary Sjogren's syndrome: consensual US-SG core items definition and reliability.** *RMD Open* 2017, **3**(1):e000364.
9. Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, Bombardieri S, Ng WF, Tzioufas AG, Vitali C *et al*: **Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren's syndrome.** *Ann Rheum Dis* 2017, **76**(7):1161-1168.
10. Fisher BA, Brown RM, Bowman SJ, Barone F: **A review of salivary gland histopathology in primary Sjogren's syndrome with a focus on its potential as a clinical trials biomarker.** *Ann Rheum Dis* 2015, **74**(9):1645-1650.
11. Cornec D, Costa S, Devauchelle-Pensec V, Chiche L, Saraux A, Pers JO: **Do high numbers of salivary gland-infiltrating B cells predict better or worse outcomes after rituximab in patients with primary Sjogren's syndrome?** *Ann Rheum Dis* 2016, **75**(6):e33.
12. Cornec D, Costa S, Devauchelle-Pensec V, Jousse-Joulin S, Marcorelles P, Berthelot JM, Chiche L, Hachulla E, Hatron PY, Goeb V *et al*: **Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome.** *J Autoimmun* 2016, **67**:102-110.
13. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK: **Towards personalised treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.** *Ann Rheum Dis* 2016, **75**(11):1933-1938.
14. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, Vissink A, Arends S, Bootsma H: **Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjogren's syndrome.** *Ann Rheum Dis* 2017, **76**(11):1883-1889.